1. Home
  2. AVAH vs NUVB Comparison

AVAH vs NUVB Comparison

Compare AVAH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aveanna Healthcare Holdings Inc.

AVAH

Aveanna Healthcare Holdings Inc.

HOLD

Current Price

$8.52

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.92

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVAH
NUVB
Founded
1984
2018
Country
United States
United States
Employees
N/A
307
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
AVAH
NUVB
Price
$8.52
$5.92
Analyst Decision
Buy
Strong Buy
Analyst Count
9
8
Target Price
$9.75
$11.38
AVG Volume (30 Days)
1.8M
4.7M
Earning Date
05-14-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
1850.00
N/A
EPS
0.19
N/A
Revenue
$2,433,199,000.00
N/A
Revenue This Year
$7.31
$203.82
Revenue Next Year
$5.59
$58.18
P/E Ratio
$44.58
N/A
Revenue Growth
20.19
N/A
52 Week Low
$3.73
$1.87
52 Week High
$10.32
$9.75

Technical Indicators

Market Signals
Indicator
AVAH
NUVB
Relative Strength Index (RSI) 76.83 63.06
Support Level $7.77 $4.13
Resistance Level $8.68 $6.06
Average True Range (ATR) 0.30 0.41
MACD 0.16 0.13
Stochastic Oscillator 94.71 69.07

Price Performance

Historical Comparison
AVAH
NUVB

About AVAH Aveanna Healthcare Holdings Inc.

Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). The Private Duty Services segment generates the majority of revenue, which includes private duty skilled nursing services, non-clinical and personal care services, and pediatric therapy services, and is principally reimbursed by Medicaid and Medicaid MCO.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: